ICON and Empire Genomics Partner for the Delivery of Personalized Medicine Services
and
Empire Genomics
announced the formation of a strategic alliance.
ICON and Empire Genomics will partner to develop a service portfolio tailored to the development of personalized medicines. The partnership combines Empire Genomics’ expertise in pharmacogenomics, computational modeling of disease state, drug disposition and drug targets with ICON’s expertise in translational medicine, clinical trial design, and biomarkers. The combined service offering will enable the identification of responder target populations, permit the stratification of patients through the development and use of companion diagnostics and will streamline drug development programs through the generation and analysis of relevant data obtained in the pre-clinical and early stage clinical setting.
“We look to partner with companies, scientists, and research institutions that complement our corporate strategies and experience, and this collaboration gives us the opportunity to work with industry leading clinical units, translational medicine expertise, and the broader ICON full-service offering,” commented Anthony Johnson, Chief Executive Officer, Empire Genomics.
“Genomics plays an integral role in personalized medicine, and through our collaboration with Empire Genomics, we can now offer sponsors integrated personalized medicine services,” commented Dr. Cyril Clarke, Vice President Translational Medicine, ICON Development Solutions. “We believe that this partnership will help sponsors to speed development by enhancing target population identification to ultimately produce safer, more effective medicines.”
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
